Impact of aldosterone antagonists on the substrate for atrial fibrillation: Aldosterone promotes oxidative stress and atrial structural/electrical remodeling

International Journal of Cardiology

Volumn 168, Issue 6, 2013, Pages 5135-5142

  Mayyas, Fadia ^a   Alzoubi, Karem H ^a   Van Wagoner, David R ^b,c  

^a JORDAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Jordan)

^b LERNER RESEARCH INSTITUTE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Aldosterone; Aldosterone antagonist; Atrial fibrillation; Oxidative stress

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN II; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ION; ENALAPRIL; EPLERENONE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SPIRONOLACTONE;

ANTIARRHYTHMIC ACTIVITY; ARTICLE; DOSE KIDNEY FUNCTION RELATION; DRUG EFFICACY; HEART ATRIUM; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART STRESS; HORMONE ACTION; HORMONE SYNTHESIS; HUMAN; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TISSUE STRUCTURE; UNSPECIFIED SIDE EFFECT;

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ATRIAL FIBRILLATION; OXIDATIVE STRESS;

ALDOSTERONE; ANIMALS; ATRIAL FIBRILLATION; ATRIAL REMODELING; HUMANS; MINERALOCORTICOID RECEPTOR ANTAGONISTS; OXIDATIVE STRESS;

EID: 84887151697     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.08.022     Document Type: Review

References (138)

1. J.H. Rennison, and D.R. Van Wagoner Impact of dietary fatty acids on cardiac arrhythmogenesis Circ Arrhythm Electrophysiol 2 2009 460 469
2. A. Goette, A. Ittenson, and P. Hoffmanns Increased expression of P-selectin in patients with chronic atrial fibrillation Pacing Clin Electrophysiol 23 2000 1872 1875
3. D. Kozlowski, S. Budrejko, and G.Y. Lip Lone atrial fibrillation: what do we know? Heart 96 2009 498 503
4. R.J. Aviles, D.O. Martin, and C. Apperson-Hansen Inflammation as a risk factor for atrial fibrillation Circulation 108 2003 3006 3010
5. M.A. Crandall, D.J. Bradley, D.L. Packer, and S.J. Asirvatham Contemporary management of atrial fibrillation: update on anticoagulation and invasive management strategies Mayo Clin Proc 84 2009 643 662
6. D.R. Van Wagoner Basic mechanisms of atrial fibrillation Cleve Clin J Med 70 Suppl. 3 2003 S2 S5
7. R.N. Goldstein, and B.S. Stambler New antiarrhythmic drugs for prevention of atrial fibrillation Prog Cardiovasc Dis 48 2005 193 208
8. E. Raschi, G. Boriani, and F. De Ponti Targeting the arrhythmogenic substrate in atrial fibrillation: focus on structural remodeling Curr Drug Targets 12 2011 263 286
9. P.K. Mehta, and K.K. Griendling Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system Am J Physiol Cell Physiol 292 2007 C82 C97
10. B. Burstein, and S. Nattel Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation J Am Coll Cardiol 51 2008 802 809
11. C. Delcayre, and B. Swynghedauw Molecular mechanisms of myocardial remodeling. The role of aldosterone J Mol Cell Cardiol 34 2002 1577 1584
12. T. Ohtani, M. Ohta, and K. Yamamoto Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: beneficial effects of mineralocorticoid receptor blocker Am J Physiol Regul Integr Comp Physiol 292 2007 R946 R954
13. D. Li, K. Shinagawa, and L. Pang Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure Circulation 104 2001 2608 2614
14. P. Milliez, N. Deangelis, and C. Rucker-Martin Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction Eur Heart J 26 2005 2193 2199
15. I.M. Bonilla, A. Sridhar, S. Gyorke, A.J. Cardounel, and C.A. Carnes Nitric oxide synthases and atrial fibrillation Front Physiol 3 2012 105
16. M.L. Ambroisine, P. Milliez, and J. Nehme Aldosterone and anti-aldosterone effects in cardiovascular diseases and diabetic nephropathy Diabetes Metab 30 2004 311 318
17. S. Nattel Aldosterone antagonism and atrial fibrillation: time for clinical assessment? Eur Heart J 26 2005 2079 2080
18. J.W. Funder Mineralocorticoid receptors: distribution and activation Heart Fail Rev 10 2005 15 22
19. S. Johar, A.C. Cave, A. Narayanapanicker, D.J. Grieve, and A.M. Shah Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase FASEB J 20 2006 1546 1548
20. M.E. Ullian, J.R. Schelling, and S.L. Linas Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses Hypertension 20 1992 67 73
21. E. Harada, M. Yoshimura, and H. Yasue Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes Circulation 104 2001 137 139
22. B.G. Newfell, L.K. Iyer, and N.N. Mohammad Aldosterone regulates vascular gene transcription via oxidative stress-dependent and -independent pathways Arterioscler Thromb Vasc Biol 31 2011 1871 1880
23. A.S. Mihailidou, M. Mardini, and J.W. Funder Rapid, nongenomic effects of aldosterone in the heart mediated by epsilon protein kinase C Endocrinology 145 2004 773 780
24. J.S. Williams Evolving research in nongenomic actions of aldosterone Curr Opin Endocrinol Diabetes Obes 20 2013 198 203
25. S.A. Cooper, A. Whaley-Connell, and J. Habibi Renin-angiotensin- aldosterone system and oxidative stress in cardiovascular insulin resistance Am J Physiol Heart Circ Physiol 293 2007 H2009 H2023
26. M.J. Mihm, C.M. Coyle, B.L. Schanbacher, D.M. Weinstein, and J.A. Bauer Peroxynitrite induced nitration and inactivation of myofibrillar creatine kinase in experimental heart failure Cardiovasc Res 49 2001 798 807
27. Y.M. Kim, T.J. Guzik, and Y.H. Zhang A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation Circ Res 97 2005 629 636
28. G.J. Babu, P. Bhupathy, C.A. Carnes, G.E. Billman, and M. Periasamy Differential expression of sarcolipin protein during muscle development and cardiac pathophysiology J Mol Cell Cardiol 43 2007 215 222
29. C.A. Carnes, M.K. Chung, and T. Nakayama Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation Circ Res 89 2001 E32 E38
30. L.E. Briggs, M. Takeda, and A.E. Cuadra Perinatal loss of Nkx2-5 results in rapid conduction and contraction defects Circ Res 103 2008 580 590
31. D.J. Grieve, J.A. Byrne, and A. Siva Involvement of the nicotinamide adenosine dinucleotide phosphate oxidase isoform Nox2 in cardiac contractile dysfunction occurring in response to pressure overload J Am Coll Cardiol 47 2006 817 826
32. A. Bukowska, C. Rocken, and M. Erxleben Atrial expression of endothelial nitric oxide synthase in patients with and without atrial fibrillation Cardiovasc Pathol 19 2010 e51 e60
33. T.L. Kaduce, X. Fang, and S.D. Harmon 20-Hydroxyeicosatetraenoic acid (20-HETE) metabolism in coronary endothelial cells J Biol Chem 279 2004 2648 2656
34. T. Anmann, M. Eimre, and A.V. Kuznetsov Calcium-induced contraction of sarcomeres changes the regulation of mitochondrial respiration in permeabilized cardiac cells FEBS J 272 2005 3145 3161
35. T. Ago, S. Matsushima, J. Kuroda, D. Zablocki, T. Kitazono, and J. Sadoshima The NADPH oxidase Nox4 and aging in the heart Aging (Albany NY) 2 2010 1012 1016
36. N. Kobayashi, H. Fukushima, and H. Takeshima Effect of eplerenone on endothelial progenitor cells and oxidative stress in ischemic hindlimb Am J Hypertens 23 2010 1007 1013
37. G.M. Kuster, E. Kotlyar, and M.K. Rude Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload Circulation 111 2005 420 427
38. C. Savoia, and E.L. Schiffrin Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions Clin Sci (Lond) 112 2007 375 384
39. M.A. Bayorh, G. Mann, M. Walton, and D. Eatman Effects of enalapril, tempol, and eplerenone on salt-induced hypertension in Dahl salt-sensitive rats Clin Exp Hypertens 28 2006 121 132
40. C.S. Ceron, M.M. Castro, and E. Rizzi Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension Br J Pharmacol 160 2010 77 87
41. J. Bauersachs, and D. Fraccarollo Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure Minerva Cardioangiol 51 2003 155 164
42. S. Kagiyama, K. Matsumura, K. Goto, T. Otsubo, and M. Iida Role of Rho kinase and oxidative stress in cardiac fibrosis induced by aldosterone and salt in angiotensin type 1a receptor knockout mice Regul Pept 160 2010 133 139
43. J. Habibi, V.G. DeMarco, and L. Ma Mineralocorticoid receptor blockade improves diastolic function independent of blood pressure reduction in a transgenic model of RAAS overexpression Am J Physiol Heart Circ Physiol 300 2011 H1484 H1491
44. G. Lastra, A. Whaley-Connell, and C. Manrique Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat Am J Physiol Endocrinol Metab 295 2008 E110 E116
45. A. Gromotowicz, J. Szemraj, and A. Stankiewicz Study of the mechanisms of aldosterone prothrombotic effect in rats J Renin Angiotensin Aldosterone Syst 12 2011 430 439
46. L. Michea, A. Villagran, and A. Urzua Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and prevents oxidative stress in uremic rats Hypertension 52 2008 295 300
47. M.A. Bayorh, A. Rollins-Hairston, J. Adiyiah, D. Lyn, and D. Eatman Eplerenone suppresses aldosterone/salt-induced expression of NOX-4 J Renin Angiotensin Aldosterone Syst 12 2011 195 201
48. H. Kawarazaki, K. Ando, and M. Fujita Mineralocorticoid receptor activation: a major contributor to salt-induced renal injury and hypertension in young rats Am J Physiol Renal Physiol 300 2011 F1402 F1409
49. Y.M. Park, M.Y. Park, Y.L. Suh, and J.B. Park NAD(P)H oxidase inhibitor prevents blood pressure elevation and cardiovascular hypertrophy in aldosterone-infused rats Biochem Biophys Res Commun 313 2004 812 817
50. E.M. Jeong, M. Liu, and M. Sturdy Metabolic stress, reactive oxygen species, and arrhythmia J Mol Cell Cardiol 52 2012 454 463
51. M. Bayeva, M. Gheorghiade, and H. Ardehali Mitochondria as a therapeutic target in heart failure J Am Coll Cardiol 61 2013 599 610
52. D.A. Pei, L. Li, and Z.Y. Xu Expression of mineralocorticoid receptor and 11-beta-hydroxysteroid dehydrogenase type 2 in human atria during chronic atrial fibrillation: study of 25 cases Zhonghua Yi Xue Za Zhi 87 2007 816 819
53. G. Kamalov, P.A. Deshmukh, and N.Y. Baburyan Coupled calcium and zinc dyshomeostasis and oxidative stress in cardiac myocytes and mitochondria of rats with chronic aldosteronism J Cardiovasc Pharmacol 53 2009 414 423
54. M.S. Seelig Consequences of magnesium deficiency on the enhancement of stress reactions; preventive and therapeutic implications (a review) J Am Coll Nutr 13 1994 429 446
55. K.T. Weber, I.C. Gerling, and M.F. Kiani Aldosteronism in heart failure: a proinflammatory/fibrogenic cardiac phenotype. Search for biomarkers and potential drug targets Curr Drug Targets 4 2003 505 516
56. X. Gao, L. Peng, C.M. Adhikari, J. Lin, and Z. Zuo Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure J Card Fail 13 2007 170 177
57. A. Whaley-Connell, and J.R. Sowers Oxidative stress in the cardiorenal metabolic syndrome Curr Hypertens Rep 14 2012 360 365
58. T. Morgera, A. Di Lenarda, and L. Dreas Electrocardiography of myocarditis revisited: clinical and prognostic significance of electrocardiographic changes Am Heart J 124 1992 455 467
59. R.H. Abdelhadi, M.K. Chung, and D.R. Van Wagoner New hope for the prevention of recurrent atrial fibrillation Eur Heart J 25 2004 1089 1090
60. P. Bruins, H. V., and A.P. Yazdanbakhsh Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia Circulation 96 1997 3542 3548
61. D.S. Conway, P. Buggins, E. Hughes, and G.Y. Lip Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation Am Heart J 148 2004 462 466
62. G.M. Marcus, M.A. Whooley, D.V. Glidden, L. Pawlikowska, J.G. Zaroff, and J.E. Olgin Interleukin-6 and atrial fibrillation in patients with coronary artery disease: data from the Heart and Soul Study Am Heart J 155 2008 303 309
63. R.B. Schnabel, K.F. Kerr, and S.A. Lubitz Large-scale candidate gene analysis in whites and African Americans identifies IL6R polymorphism in relation to atrial fibrillation: the National Heart, Lung, and Blood Institute's Candidate Gene Association Resource (CARe) project Circ Cardiovasc Genet 4 2011 557 564
64. L.C. Sturgis, J.G. Cannon, D.A. Schreihofer, and M.W. Brands The role of aldosterone in mediating the dependence of angiotensin hypertension on IL-6 Am J Physiol Regul Integr Comp Physiol 297 2009 R1742 R1748
65. K.C. Gilbert, and N.J. Brown Aldosterone and inflammation Curr Opin Endocrinol Diabetes Obes 17 2010 199 204
66. B. Klanke, N. Cordasic, A. Hartner, R.E. Schmieder, R. Veelken, and K.F. Hilgers Blood pressure versus direct mineralocorticoid effects on kidney inflammation and fibrosis in DOCA-salt hypertension Nephrol Dial Transplant 23 2008 3456 3463
67. R. Rocha, C.L. Martin-Berger, P. Yang, R. Scherrer, J. Delyani, and E. McMahon Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart Endocrinology 143 2002 4828 4836
68. Y. Sun, J. Zhang, L. Lu, S.S. Chen, M.T. Quinn, and K.T. Weber Aldosterone-induced inflammation in the rat heart: role of oxidative stress Am J Pathol 161 2002 1773 1781
69. Y. Hirono, T. Yoshimoto, and N. Suzuki Angiotensin II receptor type 1-mediated vascular oxidative stress and proinflammatory gene expression in aldosterone-induced hypertension: the possible role of local renin-angiotensin system Endocrinology 148 2007 1688 1696
70. W. Zhao, T. Zhao, Y. Chen, R.A. Ahokas, and Y. Sun Oxidative stress mediates cardiac fibrosis by enhancing transforming growth factor-beta1 in hypertensive rats Mol Cell Biochem 317 2008 43 50
71. U.D.D. Lendeckel, and A. Goette Aldosterone-receptor antagonism as a potential therapeutic option for atrial fibrillation Br J Pharmacol 159 2010 1581 1583
72. N. Kobayashi, K. Yoshida, and S. Nakano Cardioprotective mechanisms of eplerenone on cardiac performance and remodeling in failing rat hearts Hypertension 47 2006 671 679
73. E. Kotlyar, J.A. Vita, and M.R. Winter The relationship between aldosterone, oxidative stress, and inflammation in chronic, stable human heart failure J Card Fail 12 2006 122 127
74. J.M. Luther, J.V. Gainer, and L.J. Murphey Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism Hypertension 48 2006 1050 1057
75. T. Doi, T. Sakoda, and T. Akagami Aldosterone induces interleukin-18 through endothelin-1, angiotensin II, Rho/Rho-kinase, and PPARs in cardiomyocytes Am J Physiol Heart Circ Physiol 295 2008 H1279 H1287
76. H.D. Xiao, S. Fuchs, and D.J. Campbell Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death Am J Pathol 165 2004 1019 1032
77. C.G. Brilla, R.C. Funck, and H. Rupp Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease Circulation 102 2000 1388 1393
78. B. Pitt, F. Zannad, and W.J. Remme The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators N Engl J Med 341 1999 709 717
79. F.J. Ramires, Y. Sun, and K.T. Weber Myocardial fibrosis associated with aldosterone or angiotensin II administration: attenuation by calcium channel blockade J Mol Cell Cardiol 30 1998 475 483
80. Y. Sun, F.J. Ramires, and K.T. Weber Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion Cardiovasc Res 35 1997 138 147
81. T. Thum, and J. Borlak Gene expression in distinct regions of the heart Lancet 355 2000 979 983
82. H.S. Hwang, G. Cirrincione, D.P. Thomas, R.J. McCormick, and M.O. Boluyt Aldosterone antagonism fails to attenuate age-associated left ventricular fibrosis J Gerontol A Biol Sci Med Sci 62 2007 382 388
83. J.G. Burniston, A. Saini, L.B. Tan, and D.F. Goldspink Aldosterone induces myocyte apoptosis in the heart and skeletal muscles of rats in vivo J Mol Cell Cardiol 39 2005 395 399
84. A.T. Beggah, B. Escoubet, and S. Puttini Reversible cardiac fibrosis and heart failure induced by conditional expression of an antisense mRNA of the mineralocorticoid receptor in cardiomyocytes Proc Natl Acad Sci U S A 99 2002 7160 7165
85. S.S. Yang, W. Han, and H.Y. Zhou Effects of spironolactone on electrical and structural remodeling of atrium in congestive heart failure dogs Chin Med J (Engl) 121 2008 38 42
86. B. Burstein, E. Libby, A. Calderone, and S. Nattel Differential behaviors of atrial versus ventricular fibroblasts: a potential role for platelet-derived growth factor in atrial-ventricular remodeling differences Circulation 117 2008 1630 1641
87. E. Sanchez-Guerrero, V.C. Midgley, and L.M. Khachigian Angiotensin II induction of PDGF-C expression is mediated by AT1 receptor-dependent Egr-1 transactivation Nucleic Acids Res 36 2008 1941 1951
88. M.F. Neves, F. Amiri, A. Virdis, Q.N. Diep, and E.L. Schiffrin Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy Can J Physiol Pharmacol 83 2005 999 1006
89. A. Fiebeler, F. Schmidt, and D.N. Muller Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury Hypertension 37 2001 787 793
90. T. Nishioka, M. Suzuki, and K. Onishi Eplerenone attenuates myocardial fibrosis in the angiotensin II-induced hypertensive mouse: involvement of tenascin-C induced by aldosterone-mediated inflammation J Cardiovasc Pharmacol 49 2007 261 268
91. X. Li, Y. Meng, X.S. Yang, P.S. Wu, and Z.S. Zhang Aldosterone stimulating PDGF-B expression in HSC via activation of EGR-1 Zhonghua Gan Zang Bing Za Zhi 13 2005 567 570
92. A. Caligiuri, R.M. De Franco, and R.G. Romanelli Antifibrogenic effects of canrenone, an antialdosteronic drug, on human hepatic stellate cells Gastroenterology 124 2003 504 520
93. B. Macunluoglu, H. Arikan, and A. Atakan Effects of spironolactone in an experimental model of chronic cyclosporine nephrotoxicity Transplant Proc 40 2008 273 278
94. F. Mayyas, M. Niebauer, and A. Zurick Association of left atrial endothelin-1 with atrial rhythm, size, and fibrosis in patients with structural heart disease Circ Arrhythm Electrophysiol 3 2010 369 379
95. O. Adam, D. Lavall, and K. Theobald Rac1-induced connective tissue growth factor regulates connexin 43 and N-cadherin expression in atrial fibrillation J Am Coll Cardiol 55 2010 469 480
96. W.T. Abraham, P.B. Adamson, and R.C. Bourge Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial Lancet 377 2011 658 666
97. Y. Terada, S. Ueda, and K. Hamada Aldosterone stimulates nuclear factor-kappa B activity and transcription of intercellular adhesion molecule-1 and connective tissue growth factor in rat mesangial cells via serum- and glucocorticoid-inducible protein kinase-1 Clin Exp Nephrol 16 2012 81 88
98. C.R. Asher, and A.L. Klein Transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation: ACUTE trial update Card Electrophysiol Rev 7 2003 387 391
99. Y. Cheng, K.A. Mowrey, D.R. Van Wagoner, P.J. Tchou, and I.R. Efimov Virtual electrode-induced reexcitation: a mechanism of defibrillation Circ Res 85 1999 1056 1066
100. L. Yue, J. Feng, R. Gaspo, G.R. Li, Z. Wang, and S. Nattel Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation Circ Res 81 1997 512 525
101. J.P. Benitah, and G. Vassort Aldosterone upregulates Ca(2 +) current in adult rat cardiomyocytes Circ Res 85 1999 1139 1145
102. N. Lalevee, M.C. Rebsamen, and S. Barrere-Lemaire Aldosterone increases T-type calcium channel expression and in vitro beating frequency in neonatal rat cardiomyocytes Cardiovasc Res 67 2005 216 224
103. R. Laszlo, K. Bentz, and A. Konior Effects of selective mineralocorticoid receptor antagonism on atrial ion currents and early ionic tachycardia-induced electrical remodelling in rabbits Naunyn Schmiedebergs Arch Pharmacol 382 2010 347 356
104. W.C. De Mello Intracellular and extracellular renin have opposite effects on the regulation of heart cell volume. Implications for myocardial ischaemia J Renin Angiotensin Aldosterone Syst 9 2008 112 118
105. R.F. Bosch, X. Zeng, J.B. Grammer, K. Popovic, C. Mewis, and V. Kuhlkamp Ionic mechanisms of electrical remodeling in human atrial fibrillation Cardiovasc Res 44 1999 121 131
106. J.P. Benitah, E. Perrier, A.M. Gomez, and G. Vassort Effects of aldosterone on transient outward K + current density in rat ventricular myocytes J Physiol 537 2001 151 160
107. C. Lammers, T. Dartsch, and M.C. Brandt Spironolactone prevents aldosterone induced increased duration of atrial fibrillation in rat Cell Physiol Biochem 29 2012 833 840
108. M. Christ, C. Eisen, J. Aktas, K. Theisen, and M. Wehling The inositol-1,4,5-trisphosphate system is involved in rapid effects of aldosterone in human mononuclear leukocytes J Clin Endocrinol Metab 77 1993 1452 1457
109. F. Liu, M.D. Levin, and N.B. Petrenko Histone-deacetylase inhibition reverses atrial arrhythmia inducibility and fibrosis in cardiac hypertrophy independent of angiotensin J Mol Cell Cardiol 45 2008 715 723
110. M. Christ, C. Meyer, K. Sippel, and M. Wehling Rapid aldosterone signaling in vascular smooth muscle cells: involvement of phospholipase C, diacylglycerol and protein kinase C alpha Biochem Biophys Res Commun 213 1995 123 129
111. J. Qu, F.M. Volpicelli, and L.I. Garcia Gap junction remodeling and spironolactone-dependent reverse remodeling in the hypertrophied heart Circ Res 104 2009 365 371
112. J.C. Reil, M. Hohl, and S. Selejan Aldosterone promotes atrial fibrillation Eur Heart J 33 2011 2098 2108
113. B.R. Palmer, A.P. Pilbrow, and C.M. Frampton Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction Eur Heart J 29 20 2008 2489 2496
114. F. Edelmann, A. Tomaschitz, and R. Wachter Serum aldosterone and its relationship to left ventricular structure and geometry in patients with preserved left ventricular ejection fraction Eur Heart J 33 2012 203 212
115. P. De-An, L. Li, and X. Zhi-Yun Increased expression of mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase type 2 in human atria during atrial fibrillation Clin Cardiol 33 2010 23 29
116. T.Y. Luo, X.H. Liu, and X. Du Effects of perindopril and spirolactone on plasma aldosterone and left atrial remodeling in a canine model of atrial fibrillation Zhonghua Xin Xue Guan Bing Za Zhi 37 2009 626 629
117. O. Amir, R.E. Amir, H. Paz, R. Mor, M. Sagiv, and B.S. Lewis Aldosterone synthase gene polymorphism as a determinant of atrial fibrillation in patients with heart failure Am J Cardiol 102 2008 326 329
118. U. Dixen, L. Ravn, and C. Soeby-Rasmussen Raised plasma aldosterone and natriuretic peptides in atrial fibrillation Cardiology 108 2007 35 39
119. A. Goette, P. Hoffmanns, W. Enayati, U. Meltendorf, J.C. Geller, and H.U. Klein Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation Am J Cardiol 88 2001 906 909 [A8]
120. B.B.R. Wozakowska-Kaplon, and G. Janiszewska A decrease in serum aldosterone level is associated with maintenance of sinus rhythm after successful cardioversion of atrial fibrillation Pacing Clin Electrophysiol 33 2010 561 565
121. R.B. Schnabel, M.G. Larson, and J.F. Yamamoto Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community Circulation 121 2010 200 207
122. J. Zhao, J. Li, and W. Li Effects of spironolactone on atrial structural remodelling in a canine model of atrial fibrillation produced by prolonged atrial pacing Br J Pharmacol 159 2010 1584 1594
123. S.C. Shroff, K. Ryu, N.L. Martovitz, B.D. Hoit, and B.S. Stambler Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure J Cardiovasc Electrophysiol 17 2006 534 541
124. R. Bafford, X.X. Sui, and M. Park Mineralocorticoid receptor expression in human venous smooth muscle cells: a potential role for aldosterone signaling in vein graft arterialization Am J Physiol Heart Circ Physiol 301 2011 H41 H47
125. Y. Ito, H. Yamasaki, and Y. Naruse Effect of eplerenone on maintenance of sinus rhythm after catheter ablation in patients with long-standing persistent atrial fibrillation Am J Cardiol 111 2013 1012 1018
126. K. Swedberg, F. Zannad, and J.J. McMurray Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study J Am Coll Cardiol 59 2012 1598 1603
127. A. Cittadini, M.G. Monti, and J. Isgaard Aldosterone receptor blockade improves left ventricular remodeling and increases ventricular fibrillation threshold in experimental heart failure Cardiovasc Res 58 2003 555 564
128. M. Kimura, H. Ogawa, and T. Wakeyama Effects of mineralocorticoid receptor antagonist spironolactone on atrial conduction and remodeling in patients with heart failure J Cardiol 57 2011 208 214
129. P. Mulder, V. Mellin, and J. Favre Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone Eur Heart J 29 2008 2171 2179
130. T. Nariai, K. Fujita, M. Mori, S. Katayama, S. Hori, and K. Matsui SM-368229, a novel promising mineralocorticoid receptor antagonist, shows antihypertensive efficacy with minimal effect on serum potassium level in rats J Cardiovasc Pharmacol 59 2012 458 464
131. M. Hayashi, T. Tsutamoto, and A. Wada Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction Circulation 107 2003 2559 2565
132. R. Dabrowski, A. Borowiec, and E. Smolis-Bak Effect of combined spironolactone-beta-blocker ± enalapril treatment on occurrence of symptomatic atrial fibrillation episodes in patients with a history of paroxysmal atrial fibrillation (SPIR-AF study) Am J Cardiol 106 2010 1609 1614
133. R. Dabrowski, C. Sosnowski, E. Michalak, and H. Szwed A beneficial effect of 3-year spironolactone therapy supplementing atenolol therapy on the remodeling of atria and ventricles in a patient with permanent atrial fibrillation Intern Emerg Med 4 2009 171 173
134. B. Pitt, W. Remme, and F. Zannad Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 2003 1309 1321
135. B. Richter, M. Derntl, M. Marx, P. Lercher, and H.D. Gossinger Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: no effect on ablation outcome after ablation of atrial fibrillation Am Heart J 153 2007 113 119
136. R. Khatib, P. Joseph, M. Briel, S. Yusuf, and J. Healey Blockade of the renin-angiotensin-aldosterone system (RAAS) for primary prevention of non-valvular atrial fibrillation: a systematic review and meta analysis of randomized controlled trials Int J Cardiol 165 1 2012 17 24
137. A.S. Desai, E.F. Lewis, and R. Li Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction Am Heart J 162 2011 966 972 [e10]
138. G.P. Rossi, T.M. Seccia, and V. Gallina Prospective appraisal of the prevalence of primary aldosteronism in hypertensive patients presenting with atrial flutter or fibrillation (PAPPHY Study): rationale and study design J Hum Hypertens 27 3 2012 158 163